Altering the clinical course of Sorsby fundus dystrophy with the use of anti-vascular endothelial growth factor intraocular therapy.
Altering the clinical course of Sorsby fundus dystrophy with the use of anti-vascular endothelial growth factor intraocular therapy.
复制标题
DOI：
10.1097/icb.0000000000000103
复制
发表时间：
2015-01-01
影响因子：
--
通讯作者：
Casaroli-Marano, Ricardo P
中科院分区：
文献类型：
--
作者：
Keller, Johannes;Giralt, Juan;Casaroli-Marano, Ricardo P
目的：Sorsby眼底营养不良是一种罕见的遗传性疾病，引起脉络膜新生血管导致视力丧失。以前，治疗大多不成功。在这里，我们分析的结果，管理多年来的各种治疗。方法：回顾性病例说明review.PATIENTS：三名成年人从一个西班牙家庭与Sorsby眼底营养不良表现出非常多样化的过程。未经治疗的病例在就诊时是盲的。光动力疗法和玻璃体内抗血管内皮生长因子药物管理修改的历史，更成功地与后者。结论：玻璃体内管理的抗血管内皮生长因子药物似乎可以减少Sorsby眼底营养不良的瘢痕形成的程度，虽然没有停止发作复发。这可能会导致改善的结果，即使当视力受损。
PURPOSE: Sorsby fundus dystrophy is a rare hereditary condition causing choroidal neovascularization leading to vision loss. Previously, treatment was mostly unsuccessful. Here, we analyze the result of various treatments administered over the years.METHODS: Retrospective case-note review.PATIENTS: Three adults from a Spanish family with Sorsby fundus dystrophy showed a very varied course. The untreated case was blind at presentation. Administration of photodynamic therapy and intravitreal anti-vascular endothelial growth factor agents managed to modify the history of disease, more successfully with the latter.CONCLUSION: The intravitreal administration of anti-vascular endothelial growth factor agents seems to reduce the extent of scarring in Sorsby fundus dystrophy albeit without halting the episodic recurrences. This may lead to improved outcomes even when the visual acuity is compromised.